REPROCELL highlights the power of human fresh tissue in global publication
05 July 2021
This article explains the benefits of human fresh tissue testing in drug discovery, describing studies where these assays have helped clinical trials.
REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite
29 June 2021
Read more about REPROCELL's new Seed iPSC Manufacture Suite to provide supply for the increasing demand of iPSC-derived Master Cell Banks
Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan
24 May 2021
The administrations of Stemchymal have been completed to all enrolled patients in phase II clinical trial for the treatment of SCA in Japan.
VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL
18 May 2021
Read more about how REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.
19 April 2021
Read about REPROCELL Bioserve's launch of new clinical oncology diagnostic services featuring NGS-based genomic profiling, targeting a wide range of cancers
Launch of New Testing Service of Identification for Covid-19 Variants
08 April 2021
REPROCELL has launched a new testing service of identification for Covid-19 variants using Allplex SARS-CoV-2 Variants I Assay manufactured by Seegene Inc.
REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan
22 March 2021
Find out more about REPROCELL's collaboration with Blacktrace Holdings Ltd in the domestic sales of their Nadia series: a single-cell analytical system.
REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products
17 March 2021
We are pleased to announce that the REPROCELL Regenerative Medicine Center has been certified as a manufacturing facility for cell culture products.
Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease
15 March 2021
Hoth Therapeutics has executed a partnership agreement with REPROCELL to assess the effect of its HT-003 therapeutic platform on tissue from IBD donors.
New publication on RNA reprogramming of endothelial progenitor cells to make clinically -relevant iPSCs
01 March 2021
Read about REPROCELL's contribution to a novel publication detailing advancements in iPSC reprogramming. The paper describes techniques for reprogramming EPCs
REPROCELL launches PCR Testing Service for COVID-19
01 March 2021
Read REPROCELL's announcement that it will launch a new PCR testing service for COVID-19 from March 2021 in collaboration with DNAFORM Inc.
REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®
25 February 2021
Read about the phase II clinical trial of Stemchymal, where the safety and efficacy of the regenerative therapeutic will be evaluated in patients with SCA.
Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables
16 February 2021
Read Axion BioSystems announcement of Bioserve Biotechnologies Pvt Ltd (REPROCELL) as the new distributor of its Maestro systems and consumables in India.
REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers
17 December 2020
Find out more about REPROCELL's announcement that they will launch a new service to generate individual specific induced pluripotent stem cells (iPSC's)
REPROCELL Becomes VIP Supplier on Scientist.com Biotech Marketplace
10 December 2020
Find out about how REPROCELL, an industry leader in the use of human biospecimens for medical research has achieved VIP supplier status on scientist.com
REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
17 August 2020
REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations
16 July 2020
Learn more about how eTheRNA's mRNA covid vaccine, developed in partnership with REPROCELL, is designed to be protective against future viral variations.
REPROCELL’s Personal iPS Service is Launched in Japan
15 July 2020
Read more about REPROCELL's exciting new launch of its Personal iPS service, allowing customers to store cells for future regenerative medicine treatment.
Why eTheRNA's mRNA vaccine may offer a long-term solution to COVID
13 July 2020
Find out why eTheRNA's mRNA vaccine may offer a long-term solution to COVID in our interview with REPROCELL's CEO.
Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient
28 February 2020
REPROCELL is pleased to announce that the first patient has been registered and been administrated at for the Phase II clinical trial of Stemchyma.